Table 4.
Baseline pFN and EDA-FN concentrations in the plasma of patients with sepsis in relation to the APACHE II and SOFA score calculated on admission to the ICU.
| pFN (mg/L) | P value | EDA-FN (mg/L) | P value | |||
|---|---|---|---|---|---|---|
| Survivors | Nonsurvivors | Survivors | Nonsurvivors | |||
| APACHE II ≤ 20 | 137.1 (113.4-156.4) | 106.8 (66.4-122.0) | 0.031 | 6.7 (4.0-29.5) | 11.0 (6.0-23.6) | 0.841 |
| APACHE II > 20 | 157.0 (153.5-196.7) | 99.8 (62.7-159.4) | 0.029 | 4.2 (3.8-12.6) | 5.8 (2.5-23.1) | 0.727 |
| SOFA ≤ 12 | 152.3 (113.4-168.2) | 93.1 (56.7-133.6) | 0.002 | 7.7 (4.0-29.5) | 7.6 (2.9-21.2) | 0.584 |
| SOFA > 12 | 138.8 (119.3-154.6) | 109.9 (62.7-166.6) | 0.410 | 3.9 (3.5-12.2) | 12.6 (2.8-25.6) | 0.469 |
The APACHE II scale: in survivors, 57% of patients had APACHE II ≤20, and 43% had APACHE II >20; in nonsurvivors, the proportions were reversed, i.e., 28% of patients had APACHE II ≤20, and 72% had APACHE II >20 (P = 0.023). The SOFA scale: in survivors, 87% of patients had SOFA ≤12, and 13% had SOFA >12; in nonsurvivors, the proportions were reversed, i.e., 38% of patients had SOFA ≤12, and 62% had SOFA >12 (P < 0.001).